Dronedarone. atrial fibrillation: too many questions about long-term adverse effects

    Prescrire International
    |October 14, 2010
    PubMed

    Insights

    Dronedarone is less effective than amiodarone for atrial fibrillation and has potential risks. Betablockers or amiodarone are preferred for managing atrial fibrillation due to better-documented safety profiles.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Atrial fibrillation management often starts with betablockers.
    • Amiodarone is a last resort due to adverse effects.
    • Dronedarone, similar to amiodarone, is a newer option.

    Purpose of the Study:

    • To evaluate dronedarone's efficacy and safety compared to amiodarone and placebo.
    • To assess dronedarone's role in atrial fibrillation and heart failure treatment.

    Main Methods:

    • Double-blind trial comparing dronedarone and amiodarone in 504 patients.
    • Two placebo-controlled trials in heart failure patients.
    • Analysis of adverse effects including mortality, gastrointestinal, thyroid, neurological, and renal issues.

    Main Results:

    • Dronedarone showed a significantly higher failure rate (75.1%) versus amiodarone (58.8%).
    • Conflicting results in heart failure trials; increased mortality in one, no significant difference in another.
    • Dronedarone has arrhythmogenic effects and other adverse events like GI issues, but fewer thyroid and neurological issues than amiodarone.

    Conclusions:

    • Dronedarone is less effective than amiodarone in the short term.
    • Betablockers or amiodarone are recommended over dronedarone due to better-documented safety and efficacy.
    • Long-term adverse effects of dronedarone, particularly pulmonary fibrosis, require further investigation.

    Related Concept Videos

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    Dysrhythmias VI: Management of Dysrhythmias01:25

    Dysrhythmias VI: Management of Dysrhythmias

    Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...